Cargando…
Response to Letter: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience
Autores principales: | O'Farrell, Eoin, Bird, Brian, Murphy, Con |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876174/ https://www.ncbi.nlm.nih.gov/pubmed/31802992 http://dx.doi.org/10.1177/1559325819887068 |
Ejemplares similares
-
Cost Implications of Reactive Versus Prospective Testing for
Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A
Single-Institution Experience
por: Murphy, Con, et al.
Publicado: (2018) -
Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
por: Vogel, Wendy H., et al.
Publicado: (2020) -
Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999) -
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023) -
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
por: McLeod, H. L., et al.
Publicado: (1998)